NCT07026474
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07026474
Title Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS>/=1) HNSCC (RePaIr-HN)
Acronym RePaIr-HN
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Universität des Saarlandes
Indications
Therapies
Age Groups: senior | adult
Covered Countries DEU


No variant requirements are available.